Skip to content

The predictive value of ctDNA for NSCLC patients in the follow-up after surgery

The predictive value of ctDNA for NSCLC patients in the follow-up after surgery

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036787
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Gold Standard:Biopsy or pathological results
Sequencing

Sponsors

Shanghai Cancer Center Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed primary NSCLC; 2. Tumor 1 cm on CT scan; No distant metastasis (cT1N0-1M0); Solid tumor that C/T ratio<=1, or part-solid tumor that C/T ratio<1 and diameter 0.5 to 1.5cm on CT scan; Suitable for lobectomy by both VATS or thoracotomy in preoperative evaluation; 3. ECOG performance status of 0 or 1; 4. Aged 18 to 75 years; 5. Patients who have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindication for surgery; 2. Patients who had history of thoracotomy and radiation for thoracic region; 3. Patients who had history of other malignant tumors within 5 years; 4. Pregnancy or lactation female patients.

Design outcomes

Primary

MeasureTime frame
Tumor Recurrence;SEN, SPE, ACC, AUC of ROC, PPV, NPV;

Countries

China

Contacts

Public ContactHong Hu

Shanghai Cancer Center Fudan University

huhong0997@163.com+86 18121299997

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026